These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of metabolically active drugs in the management of ischemic heart disease. Schofield RS; Hill JA Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049 [TBL] [Abstract][Full Text] [Related]
4. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391 [TBL] [Abstract][Full Text] [Related]
5. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. César LA; Gowdak LH; Mansur AP Curr Pharm Des; 2009; 15(8):841-9. PubMed ID: 19275648 [TBL] [Abstract][Full Text] [Related]
6. Trimetazidine in the myocardial cell mechanisms of cytoprotection. Labrid C Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510 [TBL] [Abstract][Full Text] [Related]
7. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease? Rizzon P; Iliceto S; Marangelli V Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732 [No Abstract] [Full Text] [Related]
8. Chronic angina: new medical options for treatment. McCullough PA Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688 [TBL] [Abstract][Full Text] [Related]
9. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Belardinelli R Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102 [TBL] [Abstract][Full Text] [Related]
10. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Lee L; Horowitz J; Frenneaux M Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367 [TBL] [Abstract][Full Text] [Related]
11. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Rupp H; Zarain-Herzberg A; Maisch B Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. Fang YH; Piao L; Hong Z; Toth PT; Marsboom G; Bache-Wiig P; Rehman J; Archer SL J Mol Med (Berl); 2012 Jan; 90(1):31-43. PubMed ID: 21874543 [TBL] [Abstract][Full Text] [Related]
15. Metabolic modulation and optimization of energy consumption in heart failure. Ferrari R; Cicchitelli G; Merli E; Andreadou I; Guardigli G Med Clin North Am; 2003 Mar; 87(2):493-507, xii-xiii. PubMed ID: 12693736 [TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications]. Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017 [TBL] [Abstract][Full Text] [Related]
17. Metabolic agents in the management of diabetic coronary patients: a new era. Celik T; Kursaklioglu H; Iyisoy A; Jata B Int J Cardiol; 2008 Jun; 127(1):133-4. PubMed ID: 17561287 [TBL] [Abstract][Full Text] [Related]
18. [Trimetazidine (Preductal). A new approach in controlling myocardial ischemia]. Eliseev OM Ter Arkh; 1996; 68(8):57-63. PubMed ID: 9019836 [No Abstract] [Full Text] [Related]